498 related articles for article (PubMed ID: 30055563)
41. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.
Tamayo I; Irache JM; Mansilla C; Ochoa-Repáraz J; Lasarte JJ; Gamazo C
Clin Vaccine Immunol; 2010 Sep; 17(9):1356-62. PubMed ID: 20631332
[TBL] [Abstract][Full Text] [Related]
42. Murine bone marrow-derived DCs activated by porcine rotavirus stimulate the Th1 subtype response in vitro.
Ye L; Jiang Y; Yang G; Yang W; Hu J; Cui Y; Shi C; Liu J; Wang C
Microb Pathog; 2017 Sep; 110():325-334. PubMed ID: 28710013
[TBL] [Abstract][Full Text] [Related]
43. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
44. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
[TBL] [Abstract][Full Text] [Related]
45. Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist.
Kim JJ; Hwang YH; Kang KY; Kim I; Kim JB; Park JH; Yoo YC; Yee ST
Int Immunopharmacol; 2014 Aug; 21(2):309-19. PubMed ID: 24859056
[TBL] [Abstract][Full Text] [Related]
46. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
Hafner AM; Corthésy B; Merkle HP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
[TBL] [Abstract][Full Text] [Related]
47. Intranasal Vaccination against HIV-1 with Adenoviral Vector-Based Nanocomplex Using Synthetic TLR-4 Agonist Peptide as Adjuvant.
Li M; Jiang Y; Gong T; Zhang Z; Sun X
Mol Pharm; 2016 Mar; 13(3):885-94. PubMed ID: 26824411
[TBL] [Abstract][Full Text] [Related]
48. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
49. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
[TBL] [Abstract][Full Text] [Related]
50. Altered Macrophage and Dendritic Cell Response in
Sánchez-Zamora YI; Juarez-Avelar I; Vazquez-Mendoza A; Hiriart M; Rodriguez-Sosa M
J Diabetes Res; 2016; 2016():7053963. PubMed ID: 27699180
[TBL] [Abstract][Full Text] [Related]
51. TLR2- and 4-independent immunomodulatory effect of high molecular weight components from Ascaris suum.
Favoretto BC; Silva SR; Jacysyn JF; Câmara NO; Faquim-Mauro EL
Mol Immunol; 2014 Mar; 58(1):17-26. PubMed ID: 24263181
[TBL] [Abstract][Full Text] [Related]
52. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands.
Idoyaga J; Moreno J; Bonifaz L
Cancer Immunol Immunother; 2007 Aug; 56(8):1237-50. PubMed ID: 17237931
[TBL] [Abstract][Full Text] [Related]
53. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
54. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector.
Rhee EG; Kelley RP; Agarwal I; Lynch DM; La Porte A; Simmons NL; Clark SL; Barouch DH
J Virol; 2010 Oct; 84(19):10413-9. PubMed ID: 20631129
[TBL] [Abstract][Full Text] [Related]
55. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
[TBL] [Abstract][Full Text] [Related]
56. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
57. Differential CD86 and CD40 co-stimulatory molecules and cytokine expression pattern induced by Trypanosoma cruzi in APCs from resistant or susceptible mice.
Planelles L; Thomas MC; Marañón C; Morell M; López MC
Clin Exp Immunol; 2003 Jan; 131(1):41-7. PubMed ID: 12519384
[TBL] [Abstract][Full Text] [Related]
58. Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.
Wüthrich M; Dobson HE; Ledesma Taira C; Okaa UJ; Dos Santos Dias L; Isidoro-Ayza M; Petrovsky N; Klein BS
mBio; 2021 Aug; 12(4):e0201821. PubMed ID: 34399628
[TBL] [Abstract][Full Text] [Related]
59. Human CD8⁺ T cells drive Th1 responses through the differentiation of TNF/iNOS-producing dendritic cells.
Chong SZ; Wong KL; Lin G; Yang CM; Wong SC; Angeli V; Macary PA; Kemeny DM
Eur J Immunol; 2011 Jun; 41(6):1639-51. PubMed ID: 21469104
[TBL] [Abstract][Full Text] [Related]
60. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors.
Rhee EG; Blattman JN; Kasturi SP; Kelley RP; Kaufman DR; Lynch DM; La Porte A; Simmons NL; Clark SL; Pulendran B; Greenberg PD; Barouch DH
J Virol; 2011 Jan; 85(1):315-23. PubMed ID: 20962088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
